161 related articles for article (PubMed ID: 38465420)
1. Selection of radionuclide(s) for targeted alpha therapy based on their nuclear decay properties.
Ree SM; Greenwood H; Young JD; Roberts R; Livens FR; Heath SL; Sosabowski JK
Nucl Med Commun; 2024 Jun; 45(6):465-473. PubMed ID: 38465420
[TBL] [Abstract][Full Text] [Related]
2. An overview of targeted alpha therapy.
Kim YS; Brechbiel MW
Tumour Biol; 2012 Jun; 33(3):573-90. PubMed ID: 22143940
[TBL] [Abstract][Full Text] [Related]
3. Modeling Cell and Tumor-Metastasis Dosimetry with the Particle and Heavy Ion Transport Code System (PHITS) Software for Targeted Alpha-Particle Radionuclide Therapy.
Lee D; Li M; Bednarz B; Schultz MK
Radiat Res; 2018 Sep; 190(3):236-247. PubMed ID: 29944461
[TBL] [Abstract][Full Text] [Related]
4. Cellular dose conversion factors for alpha-particle--emitting radionuclides of interest in radionuclide therapy.
Hamacher KA; Den RB; Den EI; Sgouros G
J Nucl Med; 2001 Aug; 42(8):1216-21. PubMed ID: 11483682
[TBL] [Abstract][Full Text] [Related]
5. Targeted alpha therapy: part I.
Elgqvist J
Curr Radiopharm; 2011 Jul; 4(3):176. PubMed ID: 22201706
[TBL] [Abstract][Full Text] [Related]
6. Theoretical estimation of absorbed dose to organs in radioimmunotherapy using radionuclides with multiple unstable daughters.
Hamacher KA; Sgouros G
Med Phys; 2001 Sep; 28(9):1857-74. PubMed ID: 11585217
[TBL] [Abstract][Full Text] [Related]
7. An alternative radiochemical separation strategy for isolation of Ac and Ra isotopes from high energy proton irradiated thorium targets for further application in Targeted Alpha Therapy (TAT).
Baimukhanova A; Engudar G; Marinov G; Kurakina E; Dadakhanov J; Karaivanov D; Yang H; Ramogida CF; Schaffer P; Magomedbekov EP; Filosofov D; Radchenko V
Nucl Med Biol; 2022; 112-113():35-43. PubMed ID: 35797877
[TBL] [Abstract][Full Text] [Related]
8. Dosimetry in targeted alpha therapy. A systematic review: current findings and what is needed.
Tronchin S; Forster JC; Hickson K; Bezak E
Phys Med Biol; 2022 Apr; 67(9):. PubMed ID: 35316802
[No Abstract] [Full Text] [Related]
9. Biodistribution study of
Sakmár M; Kozempel J; Kučka J; Janská T; Štíbr M; Vlk M; Šefc L
Nucl Med Biol; 2024; 130-131():108890. PubMed ID: 38402673
[TBL] [Abstract][Full Text] [Related]
10. Targeted Alpha Therapy: Progress in Radionuclide Production, Radiochemistry, and Applications.
Nelson BJB; Andersson JD; Wuest F
Pharmaceutics; 2020 Dec; 13(1):. PubMed ID: 33396374
[TBL] [Abstract][Full Text] [Related]
11. Targeted Alpha Therapy: Current Clinical Applications.
Guerra Liberal FDC; O'Sullivan JM; McMahon SJ; Prise KM
Cancer Biother Radiopharm; 2020 Aug; 35(6):404-417. PubMed ID: 32552031
[TBL] [Abstract][Full Text] [Related]
12. Innovation, Impact, and Strategic Importance of Alpha-Emitting Radionuclides.
Mirzadeh S
J Med Imaging Radiat Sci; 2019 Dec; 50(4 Suppl 1):S21-S25. PubMed ID: 31420270
[TBL] [Abstract][Full Text] [Related]
13. Targeted alpha therapy with bismuth-213 and actinium-225: Meeting future demand.
Bruchertseifer F; Kellerbauer A; Malmbeck R; Morgenstern A
J Labelled Comp Radiopharm; 2019 Sep; 62(11):794-802. PubMed ID: 31369165
[TBL] [Abstract][Full Text] [Related]
14. A GATE simulation study for dosimetry in cancer cell and micrometastasis from the
Koniar H; Miller C; Rahmim A; Schaffer P; Uribe C
EJNMMI Phys; 2023 Aug; 10(1):46. PubMed ID: 37525027
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and characterization of lanthanum phosphate nanoparticles as carriers for (223)Ra and (225)Ra for targeted alpha therapy.
Rojas JV; Woodward JD; Chen N; Rondinone AJ; Castano CH; Mirzadeh S
Nucl Med Biol; 2015 Jul; 42(7):614-20. PubMed ID: 25900730
[TBL] [Abstract][Full Text] [Related]
16. Comparison between Targeted Radionuclide Therapy of Bone Metastases Based on β-Emitting and α-Emitting Radionuclides.
Sadremomtaz A; Masoumi M
J Med Imaging Radiat Sci; 2019 Jun; 50(2):272-279. PubMed ID: 31176435
[TBL] [Abstract][Full Text] [Related]
17. Harnessing
Yang H; Wilson JJ; Orvig C; Li Y; Wilbur DS; Ramogida CF; Radchenko V; Schaffer P
J Nucl Med; 2022 Jan; 63(1):5-13. PubMed ID: 34503958
[TBL] [Abstract][Full Text] [Related]
18. Targeted alpha therapy using short-lived alpha-particles and the promise of nanobodies as targeting vehicle.
Dekempeneer Y; Keyaerts M; Krasniqi A; Puttemans J; Muyldermans S; Lahoutte T; D'huyvetter M; Devoogdt N
Expert Opin Biol Ther; 2016 Aug; 16(8):1035-47. PubMed ID: 27145158
[TBL] [Abstract][Full Text] [Related]
19. Dosimetric evaluation of radionuclides for VCAM-1-targeted radionuclide therapy of early brain metastases.
Falzone N; Ackerman NL; Rosales LF; Bernal MA; Liu X; Peeters SG; Soto MS; Corroyer-Dulmont A; Bernaudin M; Grimoin E; Touzani O; Sibson NR; Vallis KA
Theranostics; 2018; 8(1):292-303. PubMed ID: 29290808
[TBL] [Abstract][Full Text] [Related]
20. Targeted alpha therapy: evidence for potential efficacy of alpha-immunoconjugates in the management of micrometastatic cancer.
Allen BJ
Australas Radiol; 1999 Nov; 43(4):480-6. PubMed ID: 10901964
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
